Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) FGF19 Antibodies:
anti-Rat (Rattus) FGF19 Antibodies:
anti-Human FGF19 Antibodies:
Go to our pre-filtered search.
Human Monoclonal FGF19 Primary Antibody for ELISA, WB - ABIN523342
Shang, Guo, Honda, Saumoy, Salen, Xu: FGF15/19 protein levels in the portal blood do not reflect changes in the ileal FGF15/19 or hepatic CYP7A1 mRNA levels. in Journal of lipid research 2013
These data identify hypothalamic Fgf15 as a regulator of glucagon (show GCG Antibodies) secretion.
Fgf15 is the sonic hedgehog (show SHH Antibodies) downstream signal to control thalamic regionalization, neurogenesis, and neuronal differentiation by regulating the expression and mutual segregation of neurogenic and proneural regulatory genes.
human microbiota was able to reduce the levels of tauro-beta-muricholic acid and induce expression of FXR (show NR1H4 Antibodies) target genes Fgf15 and Shp (show LAMC1 Antibodies) in ileum after long-term colonization. We show that a human microbiota can change BA composition and induce FXR (show NR1H4 Antibodies) signaling in colonized mice, but the levels of secondary BAs produced are lower than in mice colonized with a mouse microbiota
This study demonstrates that the FGF19-SHP (show LAMC1 Antibodies)-LSD1 (show KDM1A Antibodies) axis maintains homeostasis by suppressing unnecessary autophagic breakdown of cellular components, including lipids, under nutrient-rich postprandial conditions.
The elevation in circulating levels of adiponectin and Fgf15 led to normalized hepatic and serum levels of bile acids, limited hepatic accumulation of toxic bile, attenuated inflammation, and amelioration of liver injury in the ethanol-fed mNT knockout mice.
This study reveals SHP (show LAMC1 Antibodies) as a global transcriptional partner of SREBP-2 (show SREBF2 Antibodies) in regulation of sterol biosynthetic gene networks and provides a potential mechanism for cholesterol-lowering action of FGF19.
Protective effects of farnesoid X receptor (show xpr1 Antibodies) on hepatic lipid accumulation are mediated by hepatic FXR (show NR1H4 Antibodies) and are independent of intestinal FGF15 signaling.
Intestinal PPARalpha (show PPARA Antibodies)-UDP- Glucuronyltransferases and downstream FXR (show NR1H4 Antibodies)-FGF15 signalling play vital roles in control of bile acid homeostasis and the pathological development of colitis.
a direct role of intestinal FGF15/19 in the regulation of SI P450 (show POR Antibodies) expression and may have profound implications for the prediction of drug exposure in patients with compromised hepatic P450 (show POR Antibodies) function
findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the brain's capacity to rapidly, potently, and selectively increase insulin (show INS Antibodies)-independent glucose disposal
Study demonstrates that elevated FGF19 expression or hyperactivation of FGF19/FGFR4 (show FGFR4 Antibodies) signaling in hepatocellular carcinoma cells is one of the main mechanisms of sorafenib resistance.
This is the first study to elucidate FGF19/FGFR4 (show FGFR4 Antibodies) signaling in favor of hepatocellular carcinoma cells developing from fatty liver
High expression of FGF19 is associated with hepatocellular carcinoma.
Findings show that FGF19 provides a cytoprotective role against ER stress by activating a FGFR4 (show FGFR4 Antibodies)-GSK3beta (show GSK3b Antibodies)-Nrf2 (show GABPA Antibodies) signaling cascade, suggesting targeting this signaling node as a candidate therapeutic regimen for hepatocellular carcinoma (HCC (show FAM126A Antibodies)) management.
Fibroblast growth factor 19 levels in human portal blood are higher than in arterial blood. Fibroblast growth factor 19 is released by the portal-drained viscera under fasted steady state conditions.
serum FGF19 and FGF21 (show FGF21 Antibodies) and hepatic Klotho (show KL Antibodies) expression are inversely associated with hepatic damage in children with NAFLD (show TSC2 Antibodies)
Administering FGF19, or suitable mimetic, as a pharmacological intervention to increase circulating levels of FGF19 and suppress BA synthesis by inhibiting CYP7A1 (show CYP7A1 Antibodies) gene expression is likely to provide therapeutic benefits for many PBC (show DLAT Antibodies) patients
Amplification of FGF19 was validated in independent LSCC samples. Furthermore, FGF19 stimulated LSCC cell growth in vitro. These data implicate FGF19 as a potential driver gene in LSCC with clinic characteristics as smoking.
FGF19 is able to enhance migration and invasion abilities of gastric cancer cells.
Bile acid and FGF19 levels increased after Roux-en-Y bypass, but not after intensive medial management in type 2 diabetic subjects who achieved similar improvement in glycemic control.
The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This growth factor is a high affinity, heparin dependent ligand for FGFR4. Expression of this gene was detected only in fetal but not adult brain tissue. Synergistic interaction of the chick homolog and Wnt-8c has been shown to be required for initiation of inner ear development.
fibroblast growth factor 19
, fibroblast growth factor 15